← Back to episode
Medical CaseAccuracy 3.6/5

Izzie Stevens: IL-2 Response and Metastatic Melanoma Monitoring

Izzie's scan shows shrinking metastases and no new lesions, but the plan remains watchful oncology monitoring.

In Plain English

Izzie's cancer is responding, but no one can promise how long that response will last.

What Happened in the Episode

The episode supports IL-2 treatment, shrunk metastases, no new metastases, oncology resident handoff, continued monitoring, and uncertain timeline.

Clinical Concept

Metastatic melanoma response monitoring

What ER Teams Would Evaluate

A real oncology team would monitor scans, symptoms, labs, treatment toxicity, response durability, and follow-up schedule.

Treatment and Management Overview

Episode-supported care includes continued IL-2 and observation/monitoring.

What TV Gets Right

The episode refuses to turn good scan news into a cure claim.

What TV Compresses

It compresses response criteria, labs, toxicity surveillance, and long-term oncology planning.

Sources and Further Reading